KRW
REGN icon

Kaufman Rossin Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

Kaufman Rossin Wealth’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-559
Closed -$432K – 116
2026
Q1 		$432K Sell
559
-132
-19% -$101K 0.25% 47
2025
Q4 		$534K Buy
691
+80
+13% +$54.3K 0.28% 52
2025
Q3 		$344K Buy
+611
New +$345K 0.19% 81
2025
Q2 		– Sell
-344
Closed -$218K – 183
2025
Q1 		$218K Buy
+344
New +$237K 0.16% 129

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
VF
Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Kaufman Rossin Wealth's REGN Position: Q2 2026 in Review

Kaufman Rossin Wealth sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 559 shares — an estimated $432K sold.

Kaufman Rossin Wealth first reported a position in REGN in Q1 2025 and held it in 4 quarters. The position peaked at $534K in Q4 2025. 334 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Kaufman Rossin Wealth reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Kaufman Rossin Wealth sold 559 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $432K.
  • Kaufman Rossin Wealth first reported a position in Regeneron Pharmaceuticals in Q1 2025 and held it in 4 quarters.
  • Kaufman Rossin Wealth's Regeneron Pharmaceuticals position peaked at $534K in Q4 2025.
  • 334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Kaufman Rossin Wealth's 13F filing for Q2 2026, filed 16 Jul 2026.